Sacroiliac Joint Fusion Market Size, Share & Trends Analysis Report By Treatment Type (Surgery, RF Ablation), By Indication (Trauma, Sacral Disruption), By End-user (Hospital, ASC), By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global sacroiliac joint fusion market size was valued at USD 539.30 million in 2021 and is estimated to grow at a compound annual growth rate (CAGR) of 19.0% from 2022 to 2030. Growing technological developments, several minimally invasive surgical procedures, reimbursement coverage, and initiatives by key companies are some of the key drivers of this market. As per AmeriHealth Caritas by 2018, minimally invasive sacroiliac joint fusion was covered by Medicaid programs in 44 states in the U.S. while 32 Blue Cross Blue Shield plans covered minimally invasive joint fusion by 2019. This is anticipated to increase the number of MIS sacroiliac joint fusion procedures. The COVID-19 pandemic significantly impacted the market.

This included the canceled or deferred surgeries, low demand, supply chain challenges, delays in clinical trials, and low sales. The COVID-19 pandemic has brought about a series of changes. The impact triggered by the pandemic has been strong enough to increase the need for innovation in healthcare facilities. Virtual medical services appeared to be one of the most promising possibilities for orthopedic services worldwide. In the future, there will be more virtual healthcare systems. SI-BONE, a key player in the market, reported that its operations ran at suboptimal capacity due to decreased demand for its flagship iFuse product. This was owing to the global restrictions on elective procedures due to the COVID-19 pandemic, particularly during the Q2 of 2020.

The company also expensed certain labor and overhead costs, which affected its financial performance. As case volumes began to recover, SI-BONE witnessed a more normalized operations capacity during the second half of 2020. The company initially limited its clinical study expenses from mid-March through April 2020 due to the postponement of trials in hospitals. However, by May 2020 most hospitals allowed the resumption of clinical trials thus allowing the company to continue its R&D activities during the pandemic. Technological advancements are also propelling the market growth.

The growing adoption of new materials and technologies for creating better and safer SI joint fusion systems is anticipated to fuel the market growth over the forecast period. This includes the use of additive manufacturing and 3D-printed titanium implants. The Siros Lateral Sacroiliac Joint Fusion system by Genesys Spine, for example, comprises 3D-printed implants that offer optimal stabilization. SI-BONE’s iFuse-3D implants consist of titanium plasma spray-coated 3D implants that mimic native cancellous bone and are based on self-harvesting technology. These additively manufactured and 3D-printed implants facilitate an interconnected “bone-like” surface that may improve osteointegration.

Indication Insights

On the basis of indicati0ons, the global market has been further divided into degenerative sacroiliitis, sacral disruption, and trauma. The degenerative sacroiliitis indication segment dominated the market in 2021 and accounted for the largest share of more than 38.5% of the global revenue. The key factors contributing to this growth include a high prevalence of degenerative sacroiliitis, growing awareness about the condition, and improving diagnostic capabilities for sacroiliac joint disorders. For instance, as per a study published in the National Library of Medicine, the prevalence of sacroiliac joint degeneration was found to be 65.1% in asymptomatic patients.

The study also showed that the prevalence steadily increased with age. The trauma segment, on the other hand, is expected to register the fastest growth rate during the forecast period. The use of SI joint fusion systems in trauma indications is one the most recently approved indications by the FDA, thus contributing to the high growth rate of this segment. SI-BONE received the FDA clearance for an expanded indication for the iFuse Implant System in March 2020 and a CE mark for a similar indication in January 2021.

Treatment Type Insights

The surgeries treatment type segment held the highest share of more than 41.0% of the global revenue in 2021. The increasing preference for minimally invasive surgeries due to the associated benefits, such as smaller incisions, reduced pain & scarring, and faster recovery times, is the major factor contributing to the high share of this segment. According to the Washington State Health Care Authority’s 2021 report, minimally invasive SI joint fusion surgery was found to be more effective than open fusion for reducing pain. It is also associated with a shorter length of stay at the hospitals. This, combined with the rising number of clinical studies using the MIS approach as compared to the open approach, is further anticipated to drive the segment growth.

On the other hand, the Radiofrequency (RF) ablation segment is anticipated to register the fastest growth rate over the projected period. Radiofrequency ablation provides moderate pain relief and helps restore function for daily movements. The increasing awareness levels about sacroiliac joint pain & its treatment options along with various research initiatives and high prevalence of risk factors are likely to contribute to the segment growth. The injections treatment type segment is also expected to witness lucrative growth, as injections are a part of the primary course of treatment for SI joint treatment procedures.

End-user Insights

On the basis of end-users, the global market has been further segmented into hospitals, Ambulatory Surgical Centers (ASCs), and others. The hospital end-user segment dominated the market in 2021 accounting for the largest share of more than 51% of the global revenue. The key factors contributing to the growth of this segment include a higher volume of surgeries performed in hospitals and a growing preference for minimally invasive surgeries. Furthermore, hospitals provide specialized, long-term care to patients. Moreover, treatments at these facilities are often reimbursed, thereby boosting their adoption.

The ASC end-user segment is anticipated to register the fastest CAGR from 2022 to 2030. This growth is credited to the rising number of ASCs. According to the Centers for Medicare & Medicaid Services (CMS), in March 2021, there were around 187 Medicare-certified ASCs in Washington state, 442 in Texas, 457 in Florida, 817 in California, and 368 in Georgia. As per Definitive Healthcare, LLC, there were about 9,280 active ASCs in 2019 in the U.S. These numbers are anticipated to increase over the coming years, thereby supporting the segment growth. In addition, these centers enable large volumes of surgeries in short periods, thus further driving the segment.

Regional Insights

On the basis of geographies, the global market has been divided into five regional markets, such as North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America was the dominant region in 2021 and accounted for the maximum revenue share of over 41.0% of the global market in 2021. The large share of the region can be attributed to the presence of key players, advanced healthcare infrastructure, and growing reimbursement coverage. Asia Pacific, on the other hand, is projected to grow at the fastest CAGR over the forecast years.

This growth can be attributed to the presence of a large patient pool, developing healthcare facilities, and investments by key companies in this region. SI-BONE, Inc. reported the first iFuse procedures beyond its key markets of Europe and the U.S., in countries, such as Canada, Israel, Japan, Australia, Hong Kong, New Zealand, Saudi Arabia, South Africa, and Turkey, thus expanding its regional presence. The company also reported having a reimbursement advantage over its competitors with more than 35 payor exclusives and 300 million lives covered.

Key Companies & Market Share Insights

The global market is highly competitive. Key companies deploy strategic initiatives, such as product development, launches, and sales & marketing strategies to increase product awareness and regional expansions and partnerships to strengthen their market share. Market players are also involved in conducting clinical testing of their products, patent applications, and increasing product penetration. For instance, in September 2021, PainTEQ was granted 3 patents in the U.S. for its drill-less method of stabilizing an SI joint, abrading device used in the procedure, and allograft implant respectively. All three offerings are used in the company’s minimally invasive LinQ procedure for SI joint dysfunction, thus solidifying PainTEQ’s position in the market.

In June 2020, Orthofix Medical Inc. launched FIREBIRD SI Fusion System through a limited market release in the U.S. The system uses a 3D-printed titanium bone screw that is implanted through a minimally invasive surgery for treating SI joint dysfunction. In October 2020, Orthofix received additional clearance from the FDA for its nanotechnology feature-NANOVATE to be used as part of its FIREBIRD system. This enhanced its offerings. Some of the key players in the global sacroiliac joint fusion market include:

• SI-BONE, Inc.

• PainTEQ

• CornerLoc

• SIGNUS Medizintechnik GmbH

• Globus Medical

• Orthofix Medical Inc.

• Life Spine, Inc.

• Camber Spine Technologies, LLC

• CoreLink Surgical

• Xtant Medical

• Surgalign Spine Technologies, Inc.

• Medtronic

Sacroiliac Joint Fusion Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For the purpose of this report, Grand View Research has segmented the global sacroiliac joint fusion market report on the basis of indication, treatment type, end-user, and region:

• Indication Outlook (Revenue, USD Million, 2017 - 2030)

  • Degenerative Sacroiliitis

  • Sacral Disruption

  • Trauma

• Treatment Type Outlook (Revenue, USD Million, 2017 - 2030)

  • Surgery

    • By Surgery Type

      • MIS

      • Open

    • By Approach

      • Dorsal

      • Anterior

    • By Product

      • Implants

      • Accessories

  • Injections

    • Diagnosis

    • Treatment

  • RF Ablation

• End-user Outlook (Revenue, USD Million, 2017 - 2030)

  • Hospitals

  • Ambulatory Surgical Centers

  • Others (Specialty Centers, Research & Academic Institutes)

• Regional Outlook (Revenue, USD Million, 2017 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

  • Asia Pacific

    • China

    • India

    • Japan

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia